Frontlight ResearchEarly access
Active, not recruitingNo phase
Effect of IOP Lowering on Progressive HM
Key facts
- Who runs it
- Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 152 people, planned
- Started
- 1 Jun 2023
- Expected to end
- 30 Nov 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Assigned Interventions: IOP-lowering eye drops
- Record updated
- 5 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Informed consent given, and consent form signed
- Age between 18 and 65 years
- Diagnosed with HM: spherical equivalent ≤ -6.00 diopters or AL ≥ 26.5 mm
- Progressive HM: progression in AL ≥0.05mm in the past 6 months or ≥0.1mm in the past 12 months
- IOP ≥ 10 mmHg and ≤ 21mmHg on at least 2 visits, as measured by Goldmann applanation tonometry
- Best corrected visual acuity (BCVA) ≥ 6/12, and being able to obtain adequate AL examination, fundus photographs, optical coherence tomography (OCT) and complete the VF examination
Who cannot take part
- Patients who have undergone any surgery or laser treatment affecting eye parameters during the follow-up period (within the last 1 year), such as cataract surgery
- Allergic to any kind of IOP-lowering therapy
- Patients with other serious systemic diseases, such as hypertension, heart disease, diabetes, rheumatic immune system disease, etc., who cannot tolerate long-term follow-up and eye treatment
- Combination of various serious fundus pathologies, such as proliferative diabetic retinopathy, retinal detachment, central retinal artery occlusion, etc
- Combination of chronic, recurrent or severe ocular inflammatory lesions, such as chronic or recurrent uveitis
- Patients with significant corneal or iris lesions, or severe cataract affecting fundus examination, or patients with only one eye
- Pregnant or lactating women, or those who plan to have children during the follow-up period
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Currently, whether and when intraocular pressure (IOP) lowering medication should be used in progressive high myopia (HM) to control axial elongation is still a dilemma. Randomized trials are required to evaluate whether IOP lowering influences the growth of axial length in progressive HM eyes.
The 2 groups in the trial
- Intervention armTreatment being tested
medical reduction of IOP by eyedrops
Treatment: Assigned Interventions: IOP-lowering eye drops
- control armNo study treatment, for comparison
follow up without medication
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Medically Intraocular Pressure Lowering on Progressive High Myopia
- Publications
- Record updated
- 5 November 2026